FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 325 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Breast Cancer Survivor Opens Her Own Business 17 Years After Beating... February 25, 2021 Sun Exposure Lowers Risk of Breast Cancer, Study Finds January 6, 2022 EMA Recommends Extension of Therapeutic Indications for Ibrutinib July 15, 2022 Cancer in My Community: Reducing Tobacco Use in Tunisia December 8, 2022 Load more HOT NEWS Tarlatamab Demonstrates Sustained Clinical Benefit and Potential Findings of Intracranial Activity... K9 Police Officer In Berlin Beats Breast Cancer For Second Time Olivia Newton-John Talks About Her Use Of Medical Cannabis During Cancer... ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology...
